68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine
tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.